Tixagevimab

Tixagevimab is a monoclonal antibody designed for the prevention and treatment of COVID-19. It is developed by AstraZeneca in partnership with the University of Oxford. Tixagevimab, in combination with another monoclonal antibody called cilgavimab, forms the AZD7442 long-acting antibody (LAAB) combination.

Mechanism of Action[edit | edit source]

Tixagevimab works by binding to the spike protein of the SARS-CoV-2 virus, preventing the virus from entering human cells. This mechanism of action is similar to the body's natural immune response, but tixagevimab provides immediate immunity, which can be particularly beneficial for individuals who have a compromised immune system.

Clinical Trials[edit | edit source]

Tixagevimab has undergone several clinical trials to assess its safety and efficacy. In a Phase III trial, the AZD7442 combination was found to significantly reduce the risk of developing symptomatic COVID-19.

Side Effects[edit | edit source]

Like all medications, tixagevimab can cause side effects. Common side effects include headache, fatigue, and injection site reactions. Severe side effects are rare but can include allergic reactions.

Availability[edit | edit source]

Tixagevimab is not yet widely available and is currently being used in clinical trials and emergency use situations. The availability of tixagevimab may vary depending on the country and the approval of the local health authorities.